Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBSS1113 plus azacitidine in AML or MDS
CTR20253847Phase 2Active
- Sponsor
- Chaser Therapeutics
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CT1113, azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Chaser Therapeutics. Started Sep 2025; status: active.
02
Drugs
CT1113azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20253847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253847.